This trial is withdrawn!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Influenza - Type A Strains
and you are
between 18 and 99
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type A strains and to determine if MEDI8852 has an acceptable safety profile in adults who are hospitalized with influenza caused by Type A strains.

Provided treatments

  • Drug: Oseltamivir
  • Drug: MEDI8852
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT03028909. The sponsor of the trial is MedImmune LLC and it is looking for 0 volunteers for the current phase.
Official trial title:
A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Influenza Caused by Type A Strains